Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
  • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
  • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
  • C07C315/02—Preparation of sulfones; Preparation of sulfoxides by formation of sulfone or sulfoxide groups by oxidation of sulfides, or by formation of sulfone groups by oxidation of sulfoxides
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C317/00—Sulfones; Sulfoxides
  • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
  • C07C33/40—Halogenated unsaturated alcohols
  • C07C33/46—Halogenated unsaturated alcohols containing only six-membered aromatic rings as cyclic parts
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
  • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
  • C07C69/78—Benzoic acid esters
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
  • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
  • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
  • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
  • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
  • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
  • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
  • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
  • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

• Ph is a phenyl group or a phenyl group substituted with one or two halogen atoms
• R 1 is a C1-C3 alkyl group
• R 2 is a hydrogen atom or a C 1 -C 3 alkyl group
• R 3 is a C-i-Cs alkyl group, a C4- C ⁇ cycloalkylalkyl group or a C 3 -C 6 cycloalkyl group and n is 0, 1 or 2, and their acid addition salts.
• U.S. Patent No. 4,526,983 discloses a process for making certain optical active imidazolyl propanoate antifungai compounds having the formula
• n is an integer of 3 or 4, and its acid addition salts, by diastereomeric separation using an optically active carboxylic acid ester.
• This separation process is not suitable for large scale commercial synthesis. It is laborious, low yielding and expensive.
• the present invention involves a series of important, novel compounds useful as intermediates in making chemically pure, enantiomeric compounds having antifungai activity.
• One aspect of the invention involves a novel intermediate compound of the formula m or Va having an asymmetric center as indicated by the asterisk ( * ) (i.e., an R or S absolute stereochemical configuration) and being substantially free of its opposite enantiomeric form:
• R ⁇ R" and R' may be the same or different and each is selected from alkyl, cycloalkyl or phenyl;
• R 1 and R 2 may be the same or different and each independently represents H, alkyl, phenyl, substituted phenyl or R 1 and R 2 together with the carbon to which they are attached represent the group
• Y is O, S(0) p or (CRaR b );
• R a and R b may be the same or different and each is independently selected from H, alkyl, alkoxy, phenyl, substituted phenyl, or -COOH or an alkyl, phenyl or substituted phenyl ester thereof, p is O, 1 or 2; n is 0, 1 or 2; and
• P 2 represents H or an amino protecting group.
• Another intermediate compound of the invention has the structural formula VII, wherein both asterisks ( * ) represent the same absolute stereochemical configuation (i.e., RR or SS forms), and wherei the compound is substantially free from compounds having other absolute stereochemical configurations at the asterisked ( * ) carbon centers (i.e., if the asterisks in formula VII indicate an RR form, the compound is substantially free from its SS, SR and RS forms):
• Ar represents phenyl, substituted phenyl, 2- or 3-thienyl, substituted 2- or 3-thienyl, 2- or 3-furanyl, substituted 2- or 3-furanyl, 2-, 4-or 5-imidazo!yI, 3-or 5-(1 ,2,4-triazolyl), 5-tetrazolyl, 2-, 4-or 5-thiazolyl, 2-, 4-or 5-oxazolyl, 3-, 4-or 5-isoxazolyl, 2-, 3-or 4-pyridinyl, 2-or 3- pyrrolyl, 3-or 4-pyrrazolyl, 2-benzimidazolyl, 2-benzthiazolyl, or 2-, 4-or 6- purinyl, wherein the saturated nitrogen atoms on said imidazolyl, triazolyl, tetrazolyl, benzimidazolyl, benzthiazolyl, and purinyl groups may be substituted with H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl,
• Compounds HI, Va and V ⁇ also have other possibly asymmetric carbons, i.e., the carbon attached to R 1 and R 2 or the carbon attached to NHP 2 in formula HI.
• the absolute stereochemical configuration at these other carbon centers is not limited by the present invention since in the processes described below the specific stereoconfiguration at these other carbon atoms does not affect the desired end product.
• a preferred novel intermediate compound of the invention is of the formula Va, wherein Z is O or NOH.
• R 1 is preferably H and R 2 is preferably phenyl or substituted phenyl.
• the compound of formula Va at the asterisk ( * ) carbon atom is in its R absolute stereochemical configuration.
• Another preferred intermediate of the invention is of formula
• R 1 is preferably H and R 2 is preferably phenyl.
• Ar is preferably substituted phenyl, more preferably Ar is mono, di or tri- substituted halo phenyl, e.g., 2,4-difluoro, 2,6-difluoro, 4-fluoro, 2-fluoro, 2,4-dichloro, 2,6- dichloro, 4-chloro or 2-chloro substituted phenyl.
• a particularly preferred Ar group is 2,4-difluorophenyl. Both asymmetric centers indicated by the asterisk ( * ) are preferably in their R absolute stereochemical configuration.
• both of the asymmetric carbon centers indicated by the asterisks ( * ) have the same absolute stereochemical configuration, and wherein said compound is substantially free from compounds having other absolute stereochemical configurations at such carbon centers;
• Ar represents phenyl, substituted phenyl, 2- or 3- thienyl, substituted 2- or 3-thienyl, 2- or 3-furanyl, substituted 2- or 3- furanyl, 2-,4-or 5-imidazoyl, 3-or 5-(1 ,2,4-triazolyl), 5-tetrazolyl, 2-,4- or 5- thiazolyl, 2-, 4-or 5-oxazolyl, 3-,4- or 5-isoxazolyl, 2-benzthiazolyl, or 2-,4- or 6-purinyl, wherein the saturated nitrogen atoms on said imidazolyl, triazolyl, tetrazolyl, benzimidazolyl, benzthiazolyl, and purinyl groups may be substituted with H, alkyl, substituted
• R 3 is alkyl, cycloalkyl or cycloalkylalkyl; and wherein n is 1 or 2.
• one process aspect of the invention involves reacting a compound of the formula I having an asymmetric carbon center as indicated by the asterisk ( * ) and being substantially free of its opposite enantiomeric form:
• the compound of formula I is generally commercially available or easily obtainable and inexpensive.
• the absolute stereochemical configuration of the asymmetric carbons attached to NHP 2 and to R 1 and R 2 are not important in the process of the invention.
• the former group is converted to a Z group as explained below and the latter group is eliminated prior to obtaining the desired end product.
• the compound of formula HI can then be reacted with a deprotecting agent (when P 2 is not H) to form a compound of formula IV
• the compound of formula V can then be further oxidized to form a compound of formula VI
• This cyclic ketone structure of formula VI surprisingly maintains its enantiomeric integrity at the the asterisked ( * ) carbon.
• racemization of an alpha-hydroxy ketone occurs rapidly when such ketones are treated with basic reagents.
• the compound of formula VI may be reacted with a compound of the formula Ar where M represents a metallic group to form a compound of formula v ⁇ and a lesser amount of a compound of formula Vila
• both of the asterisks in formula VII have the same absolute stereochemical configuration (i.e., RR or SS form)
• the single asterisk ( * ) carbon and the double asterisk ( ** ) carbon in formula Vila have the opposite stereochemical configuration, i.e., the single asterisk ( * ) represents an R form and the double asterisk ( ** ) an S form or single asterisk ( * ) represents an S form and double asterisk ( ** ) an R form.
• the compound of formula v ⁇ is obtained as the major product contrary to the literature (J. Am. Chem. Soc., 1987, Vol. 109, (pp. 908-910) which indicates that the opposite enantiomeric form would be obtained.
• the compound of formula VII may also be prepared by reacting the compound of formula V with an Ar 1 anion to form a compound of the formula vm where the asterisk asymmetric centers ( * ) are of the same absolute stereochemical configuration:
• the compound of formula VII can be reacted (when R1 represents H) with an oxidizing agent, such as N-halo-succinimide or halogen-water, to form a compound of formula IX where Z 1 is O and X is halogen, with a reducing agent (when R1 represents H) to form a compound of formula IX where Z 1 is H2 and X is OH, or with a hydrolyzing agent to form a triol ' of the formula IXa:
• an oxidizing agent such as N-halo-succinimide or halogen-water
• Ar 1 represents 1-(1 , 2, 4-triazolyl), 1-(1 , 3, 4-triazolyl) or 1- imidazolyl and wherein Z 1 represents H,H or O.
• the compound of formula Vila may be reacted with a mesylating agent to form a compound of the formula X wherein Ms represents a mesyl group (CH3SO2-) and the carbon centers having the single asterisk ( * ) and the double asterisks ( ** ) are of opposite absolute stereochemical configurations
• the stereochemistry in the compounds of formulas XI and XIa are inverted at the carbon attached to the Ar group with respect to the same carbon atom in the compounds of formula X.
• the compounds of the formula XI and XIa are reacted with an Ar 1 anion to form a compound of the formula x ⁇ or xm, respectively.
• the compound of formula Xi ⁇ may then be employed to prepare the desired antifungai end products of formula XVI by applying the methods known per se such as those described in European published application No. 0178533 by reacting the compound of formula Xi ⁇ with a mesylating agent to form a compound of the formula XIV
• R 3 is alkyl, cycloalkyl or cycloalkylalkyl
• n is 1 or 2.
• Ar 1 is preferably 1-(1 ,2, 4-triazolyl)
• Ar is preferably 2,4-difluorophenyl
• R 3 is preferably methyl
• n is preferably 2
• the asterisks preferably indicate the RR absolute stereochemical form of the compound.
• This invention relates to substantially pure enantiomers and to processes for making such substantially pure enantiomers.
• substantially pure we mean substantially free from any of the other enantiomeric forms of such compounds, e.g., one enantiomer is present in amounts greater than about 95 molar %, more preferably greater than about 97 molar %, most preferably greater than about 99 molar %, with respect to any other enantiomer.
• acyl - represents alkanoyl, halo-substituted alkyl carbonyl, benzoyl and substituted benzoyl; alkyl (including the alkyl portions of alkanoyl, alkylthio, alkoxy, alkyloxyalkyl, alklythioalkyl, alkanoyloxy, etc.) - represents a straight or branched hydrocarbon chain having from 1 to 12, preferably from 1 to 6, carbon atoms; amino protecting group - represents a group which will protect an amino group during a desired chemical reaction such as the reactions described above, e.g., suitable amino protecting groups include benzyl, substituted benzyl, alkoxy-substituted phenyl, acyl, alkoxycarbonyl, halo-substituted alkoxycarbonyl, unsubstituted or substituted allyloxycarbonyl, etc.;
• the asymmetric carbon center indicated by single asterisk ( * ) in formula I is preferably in its R absolute stereochemical form and will thus result in an end product of formula XVI having R absolute stereochemical configuration at both of the asterisked ( * ) carbon centers, i.e., the RR form of the compound of formula XVI. If the compound of formula I has the S absolute stereochemical configuration at the asterisked ( * ) carbon, both of the carbon atoms indicated by the asterisk ( * ) in the final product XVI will be in their S absolute stereochemical configuration, i.e., the SS form of the compound of formula XVI.
• Step A the carboxylic acid group or its suitably protected form (e.g., an ester) is reduced to a hydroxyl group.
• Any suitable reducing agent can be employed, e.g., lithium aluminium hydride (when formula I is in ester form) or diborane (when formula I is in the acid form) in a non-participating solvent such as tetrahydrofuran, diethylether and the like.
• the temperature of the reaction may range from about 0°C to a refluxing temperature, preferably about room temperature.
• excess reagent may be neutralized, e.g, using dilute acetic acid or aqueous NH4CI solution.
• the free amino group is temporarily protected either as a benzoyl group or as a benzyl group for the convenience of the extractive work up. This protecting group is usually removed before Step B by a hydrogenative process.
• Step B the amino group of formula II is usually protected by any suitable protecting group, e.g., an acyl group, preferably by a trifluoroacetyl group. Then both of the hydroxyl groups are protected as ah acetal or ketal group by reaction with an acetal or ketal forming agent of the formula R 1 R 2 CO, R1 R 2 C(Oalkyl) or R 2 CHO.
• the reaction is usually conducted under acid catalysis at temperatures ranging from about 0°C to about 100°C in any suitable solvent such as CH2CI2, toluene, etc.
• the reaction is worked up by neutralizing to about pH 7 and separating the organic layer in a conventional manner.
• Step C the amine protecting group in formula III is removed. If it is an acyl group, it is removed by conventional base hydrolysis (e.g., NaOH/H2 ⁇ ), in a suitable solvent such as ethanol, acetonitrile, etc., at about 0°C to about 60°C, preferably at about room temperature.
• a suitable solvent such as ethanol, acetonitrile, etc.
• the product may be extracted into an organic solvent such as methylene chloride, diethyl ether, etc.
• Step D the amino group of formula IV is oxidized to an oxime group ( in formula V) or directly to a carbonyl group (as in formula VI).
• the oxidation can be performed using H2O2 in presence of sodium tungstate (Na2W ⁇ 4) or by hypochlorites or by quinones.
• the oxidation is usually performed in aqueous medium in presence of a miscible organic solvent such as ethanol, methanol, dimethylsulfoxide (DMSO), dimethylformamide (DMF), etc.
• the temperature of the reaction can be from about 0°C to about 80°C, preferably at about room temperature.
• the product usually crystallizes out of the medium.
• Step E the oxime of formula V (which may be protected by a suitable protecting group P 1 ) is further oxidized using a nitrosating agent such as sodium nitrite.
• the reaction is usually performed in an aqueous medium employing an organic miscible solvent such as ethanol, DMF, DMSO, acetonitrile, etc., at about 0°C to about 40°C, preferably at about 20 to about 30°C.
• a mild acid catalyst such as acetic acid usually accelerates the oxidation to the ketone.
• This ketone of formula VI may also be obtained directly from the amine by oxidizing with a quinone reagent and the resultant imine intermediate is then hydrolyzed to the ketone during acid work up.
• the keto group of formula VI is reacted with an organometallic reagent ArM to obtain the desired adduct.
• the organo- metallic reagent can be a Grignard reagent; a lithium derivative of an alkyl or an aryl compound; a zinc, titanium, copper or tin derivative of an alkyl, aryl or substituted alkyl or aryl compound; or a silylated compound from which silicon is removed by fluoride ion to generate the reactive species.
• the reaction is usually performed in a non-participating solvent such as the aprotic solvents typically used in reactions using organometallic regents, e.g.
• the temperature of the reaction can be from about -60°C to about +80°C and preferably at about 0°C to about 25°C.
• the stereochemistry of the addition of ArM to the ketone provides the chirality as RR or SS as the predominant species VII depending on whether the starting ketone of formula VI is in the R or S form, respectively.
• Minor amounts of RS or SR isomers VTJa formed in the above reaction, depending on whether the starting ketone of formula VI is in the R or S form, respectively, may be utilized by following Steps J and K as further explained below.
• the compound of formula VII may also be obtained from the oxime of formula V as in Step G above by first reacting with ArM under conditions described in Step F. The product of formula VIII formed is then reacted in step H with a nitrosating agent such as aN ⁇ 2 in mild acid medium to nitrosate the hydroxyl amine. Loss of N2 gives substantially the desired product of formula VII.
• a nitrosating agent such as aN ⁇ 2 in mild acid medium to nitrosate the hydroxyl amine. Loss of N2 gives substantially the desired product of formula VII.
• the protecting group of the alcoholic groups (ketal or acetal group) in formula VII can be removed or partially removed as desired to obtain the primary hydroxyl group free for further reaction.
• Acid hydrolysis in aqueous medium gives the triol IXa .
• a leaving group such as a mesylate or a halogen (Cl, Br, I)
• the RS or SR diastereomer of formula Vila is converted to formula X by making the tertiary hydroxy group a leaving group such as mesylate. This is done by conventional reagents such as mesyl chloride in THF in the presence of a base (triethylamine) at about 0°C to about 50°C, preferably at about room temperature.
• a base triethylamine
• Step K which is same as Step I above, plus a base treatment (with for example triethylamine) after Step I, gives the epoxide of formula XI or XIa.
• a base treatment with for example triethylamine
• the compound of formula XII or XIII is obtained from the compound of formula IX, IXa, XI or XIa in steps M, M', L and P by reaction with a nucleophile Ar 1 anion in a suitable solvent such as DMF, DMSO, CH3CN, etc., at temperatures ranging from about 0°C to about 80°C, preferably at room temperature to about 50°C.
• a suitable solvent such as DMF, DMSO, CH3CN, etc.
• step N the protecting group on the oxygen atom in formula x ⁇ is removed by conventional methods.
• Z 1 is O
• base hydrolysis NaOH/H2 ⁇
• aqueous ethanol gives the compound of the formula Xi ⁇ .
• Z 1 is H,H
• catalytic hydrogenation provides the compound of the formula Xi ⁇ .
• the compound of the formula Xi ⁇ may also be obtained by reacting either the compound of formula XIa or IXa with an Ar 1 anion under the same conditions as in step M above.
• Steps Q, T and U may be performed as described in European published application No. 0178533.
• the compound of formula xm is reacted with a mesylating agent such as methanesulfonyl chloride (CH3SO2CI) in an inert solvent (e.g., benzene, DMF, dichloromethane, etc.) in the presence of a base at about 0°C. to about 30°C to give the methane sulfonate or mesylate of the formula XIV.
• the mesylating agent is typically employed in excess (1 to 2 equivalents).
• the base can be, for example, an organic amine, e.g., pyridine.
• the methane sulfonate or mesylate of formula XIV is then reacted in step T with a mercaptan anion of the formula R 2 S- where R 2 is alkyl, cycloalkyl or cycloalkylalkyl.
• the counterion is preferably an alkali metal salt and the solvent is preferably inert (e.g., DMSO, DMF, etc.).
• the thiol salt may be employed in excess (2 to 10 equivalents) and the temperature is typically 0 to 80°C.
• the sulfide of the formula XV is then oxidized in step U using an oxidizing agent such as a peracid, e.g., meta-chloroperbenzoic acid, in an inert solvent, e.g., chloroform, at a temperature of from about - 30C to reflux.
• an oxidizing agent such as a peracid, e.g., meta-chloroperbenzoic acid
• an inert solvent e.g., chloroform

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Plural Heterocyclic Compounds (AREA)
• Peptides Or Proteins (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=23590795

Family Applications (2)

Family Applications After (1)

Country Status (10)

Families Citing this family (3)

Family Cites Families (4)

• 1990
  • 1990-08-30 KR KR1019920700463A patent/KR927003566A/ko not_active Ceased
  • 1990-08-30 IL IL95539A patent/IL95539A0/xx unknown
  • 1990-08-30 ZA ZA906933A patent/ZA906933B/xx unknown
  • 1990-08-30 WO PCT/US1990/004842 patent/WO1991003473A1/en not_active Ceased
  • 1990-08-30 IE IE314590A patent/IE903145A1/en unknown
  • 1990-08-30 AU AU63463/90A patent/AU6346390A/en not_active Abandoned
  • 1990-08-30 EP EP90913304A patent/EP0489818A1/de active Pending
  • 1990-08-30 PT PT95157A patent/PT95157A/pt not_active Application Discontinuation
  • 1990-08-30 CA CA002065259A patent/CA2065259A1/en not_active Abandoned
  • 1990-08-30 EP EP90309475A patent/EP0415748A1/de not_active Ceased
  • 1990-09-07 MY MYPI90001501A patent/MY106469A/en unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events